Traffic Lights - Latest Updates

Last updated: 12/11/2021

Other updates on this site
Drug Name Classification Clinical Indication Comments
ABATACEPT (UPDATED) Red Rheumatoid arthritis

In line with NICE TA 195 and NICE TA 280 and NICE TA715

ABROCITINIB (Cibinqo ®) (NEW) Grey Treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy

Not yet reviewed

ACITRETIN (UPDATED) Red For psoriasis, Icthyosis, palmoplantar pustulosis and Dariers disease in males and postmenopausal women.

Reviewed by TAS 22nd June 2021

ADALIMUMAB (UPDATED) Red Moderate rheumatoid arthritis.

In line with NICE TA715

ALBUTREPENONACOG ALPHA (Idelvion®) (NEW) Red Prophylaxis and treatment of bleeding in Haemophilia B
ALPHA-TOCOPHEROL (VITAMIN E) (NEW) Red When given with pentoxifylline or the treatment of persistently thin endometrium during IVF therapy
AMIKACIN (Arikayce Liposomal®) (NEW) Grey Non-tuberculous mycobacterial (NTM) lung infections

Not yet reviewed

ANAKINRA (Kineret®) (NEW) Red Still’s disease and juvenile idiopathic arthritis

In line with NICE TA685

Implementation date 30th June

ANDEXANET ALFA (Ondexxya®) (NEW) Red Reversing anticoagulation from apixaban or rivaroxaban in adults for life-threatening or uncontrolled GI bleed.

In line with NICE TA697

ASCORBIC ACID PASCOE 150 MG/ML CONCENTRATE FOR SOLUTION FOR INJECTION / INFUSION (NEW) Grey Treatment of clinical vitamin C deficiency

Not yet reviewed

AVATROMBOPAG (Doptelet®) (NEW) Grey Severe thrombocytopenia

Not yet reviewed

AZATHIOPRINE (NEW) Orange Autoimmune neurological disorders

Please see shared care agreement for individual indications

BARICITINIB (NEW) Red Moderate to severe atopic dermatitis

In line with NICE TA681

Implementation date 3rd June 2021

BElIMUMAB (UPDATED) Red Active autoantibody-positive systemic lupus erythematosus. Rheumatology only
BEMPEDOIC ACID (Nilemdo®) (UPDATED) Red Primary hypercholesterolaemia or mixed dyslipidaemia in adults

In line with NICE TA694

Implementation date 28th July 2021

BEMPEDOIC ACID / EZETIMIBE (Nustendi®) (UPDATED) Red Primary hypercholesterolaemia or mixed dyslipidaemia in adults

In line with NICE TA694

Implementation date 28th July 2021

BEROTRALSTAT (NEW) Red Prevention of recurrent attacks of hereditary angioedema (HEA)
BIMEKIZUMAB (Bimzelx®) (NEW) Red Moderate to severe plaque psoriasis

In line with NICE TA723

BOTULINUM TOXIN B (Neurobloc®) (UPDATED) Red Neurology use only
BUDESONIDE (1mg orodipersible tablet) (Jorveza®) (UPDATED) Red For treatment of eosinophilic esophagitis in adults and children

NICE TA708

BUPRENORPHINE PROLONGED RELEASE INJECTION (Buvidal®) Red Substance misuse

Used by Turning Point . If a patient is admitted to hospital contact turning point for advice about alternatives:

0116 3732117 – Direct dial to prescribing team

0116 3732108 – Direct Dial to Clinical Admin

0330 303 6000 – Main Switchboard

BUSPIRONE (NEW) Red Gastroparesis/functional dyspepsia
CASIRIVIMAB AND IMDEVIMAB (Ronapreve®) (NEW) Red For patients hospitalised due to COVID-19
CHLOROPROCAINE HYDROCHLORIDE (Ampres®) (NEW) Do not prescribe Spinal anesthesia for orthopedic & urology day cases lasting 40 to 60 mins

Reviewed by TAS September 2021

COLISTIN (NEW) Red Nebulised for Cystic fibrosis
COLISTIN (Colomycin® and Promixin ®) Orange Nebulised for cystic fibrosis

Historic patients only. Must be prescribed by brand as the brands are not interchangeable.

DALBAVANCIN (Xydalba®) (NEW) Red Osteoarticular infections (unlicensed)
DEFLAZACORT (Calcort®) (NEW) Red Duchenne muscular dystrophy
DEXMEDETOMIDINE (Dexdor ®) (NEW) Red Pre procedure sedation in children
DULOXETINE (NEW) Green Anxiety and depression
EMTRICITABINE/TENOFOVIR DISOPROXIL (Ictastan®) (UPDATED) Red HIV
ESKETAMINE HYDROCHLORIDE NASAL SPRAY (Spravato®) (UPDATED) Red In combination with a SSRI or SNRI for adults with treatment-resistant Major Depressive Disorder

Administration in specialist clinic only

ESTRADIOL VAGINAL TABLETS (Vagirux®) (NEW) Green Vaginal atropy in post menopausal women
ETANERCEPT (NEW) Red Moderate rheumatoid arthritis.

In line with NICE TA715

FILGOTINIB (Jyseleca®) (NEW) Red Moderate to severe arthritis

In line with NICE TA676

Implementation date 24th May 2021

FLUTICASONE/UMECLIDINIUM/VILANTEROL DRY POWDER INHALER (Trelegy Ellipta®) (NEW) Do not prescribe COPD

Reviewed by the respiratory group

GALANTAMINE Gazylan XL ® (UPDATED) Yellow Alzheimer's disease
GALANTAMINE LIQUID (UPDATED) Red Alzheimer's disease

Leicestershire Partnership Trust consultants only

GLYCEROL PHENYLBUTYRATE (Ravicti®) (UPDATED) Red Chronic management of patients with urea cycle disorders (UCDs)
GLYCOPYRONIUM/BECLOMETASONE/FORMETEROL DPI (Trimbow NEXThaler) (NEW) Green Maintenance treatment of adults with moderate to severe COPD

Reviewed by the Respiratory Prescribing Group September 2021

GUSELKUMAB (NEW) Red Treating active psoriatic arthritis after inadequate response to DMARDs

In line with NICE TA711

Herpes ZOSTER vaccine (UPDATED) Do not prescribe All indications outside of the green book. Zostavax is a live vaccine, therefore NOT suitable for immunocompromised patients. Do not prescribe on FP10 (black through this route).

Available centrally from 1st Sept 2013 for those aged 70 and 79 years
Public Health advice

HUMAN FIBRINOGEN & HUMAN THROMBIN (Veraseal®) (NEW) Red Supportive treatment in adults where standard surgical techniques are insufficient; for improvement of haemostasis & as suture support in vascular surgery
HYDROXYCHLOROQUINE (UPDATED) Yellow Rheumatological disease

Eye checks to be organised by secondary care.

IMIPENEM/CILASTATIN/ RELEBACTAM (Recarbrio®) (UPDATED) Red Aerobic Gram-negative infections
INDACATEROL/MOMETASONE dry powder inhaler (Atectura Breezhaler®) (NEW) Grey Maintenance treatment of asthma in adults and adolescents 12 years of age and older

Not yet reviewed

INFLIXIMAB (NEW) Red Moderate rheumatoid arthritis.

In line with NICE TA715

IXEKIZUMAB (Taltz®) (NEW) Red Axial spondyloarthritis

In line with NICE TA718

Implementation date 21st October

LEUPRORELIN (PROSTAP 3 DCS ®) (NEW) Yellow Breast cancer

3 monthly preparation

LURASIDONE (UPDATED) Orange Schizophrenia aged 13-17 years

Full SCA  Request form

LUSUTROMBOPAG (Mulpleo®) (NEW) Grey Severe thrombocytopenia

Not yet reviewed

MBrIDA (NEW) Red Diagnosis of hepatobiliary tract patency and differentiation of jaundice
MOMETASONE/ OLOPATADINE NASAL SPRAY (Ryaltris ®) (NEW) Grey Moderate to severe nasal symptoms associated with allergic rhinitis

Not yet reviewed

MYCOPHENOLATE MOFETIL (NEW) Orange Autoimmune conditions

Please see shared care agreement for individual indications

NONACOG BETA PEGOL (Refixia®) (UPDATED) Red Haemophilia
OFATUMUMAB (Kesimpta ®) (NEW) Red For treating relapsing multiple sclerosis

In line with NICE TA699

Implementation date 19th August 2021

ONASEMNOGENE ABEPARVOVEC (Zolgensma®) (NEW) Grey 5q spinal muscular atrophy (SMA)

Not yet reviewed

OPIATE/MORPHINE TINCTURE (Dropizol® oral drops) (NEW) Do not prescribe Severe diarrhoea

Reviewed by TAS 22nd June 2021

OPTIVE PLUS (UPDATED) Do not prescribe Dry eye
OXANDROLONE (UPDATED) Red Prophylaxis of acute attacks in hereditary angioedema. Third line after danazol and stanozolol when stanozolol is unavailable
PENTOXIFYLLINE (Trental®) (NEW) Red When given with alpha tocopherol (vitamin E) for the treatment of persistently thin endometrium during IVF therapy
PERGOLIDE (UPDATED) Do not prescribe Parkinson's disease

No longer recommended

PONESIMOD (Ponvory®) (NEW) Grey Relapsing forms of multiple sclerosis with active disease.

Not yet reviewed

PRIDINOL (Myopridin®) (NEW) Grey Central and peripheral muscle spasms, lumbar pain, torticollis and general muscle pain

Not yet reviewed

PROGESTERONE SC INJECTION (Lubion®) (NEW) Do not prescribe Luteal Phase Support for assisted reproduction treatment (IVF/ICSI)

Reviewed by TAS September 2021

QUINIDINE (NEW) Red KCNT1 gene mutation related Early Infantile Epileptic Encephalopathy

Reviewed by TAS September 2021

RAVULIZUMAB (UPDATED) Red Treating atypical haemolytic uraemic syndrome (aHUS)

Only for use in specialist centres or in secondary care under an agreed tertiary centre as per NICE TA710.

RAVULIZUMAB (Ultomiris®) (UPDATED) Do not prescribe Paroxysmal nocturnal haemoglobinuria

In line with NICE TA698 this product should be used by specialist centres only. At the time of classification LLR is not a site of a specialist centre.

REMIMAZOLAM (Byfavo®) (NEW) Grey Procedural sedation in adults.

Not yet reviewed

SECUKINUMAB (Cosentyx®) (NEW) Red Non-radiographic axial spondyloarthritis

In line with NICE TA719

Implementation date 21st October 2021

SEMAGLUTIDE (Rybelsus®) (UPDATED) Green Type 2 diabetes
SIMPLE EYE OINTMENT (UPDATED) Do not prescribe Dry eye
SOLRIAMFETOL (Sunosi ®) (UPDATED) Red Excessive daytime sleepiness in narcolepsy
SOLRIAMFETOL (Sunosi ®) (UPDATED) Red Residual sleepiness in optimally CPAP treated obstructive sleep apnoea
SUGAMMADEX (Bridion®) (UPDATED) Red Reversal of neuromuscular blockage induced by rocuronium or vecuronium
TACROLIMUS (Advagraf®) (NEW) Red Continuation of hepatic transplant immunosuppression for patients transferred from out of area tertiary centre only
TRALOKINUMAB (Adtralza ®) (NEW) Grey Treatment of moderate-to-severe atopic dermatitis in adult

Not yet reviewed

TRANSDERMAL ESTRADIOL SPRAY (Lenzetto®) (NEW) Green Symptoms of menopause
TRI-IODOTHYROACETIC ACID (TRIAC) (Emcitate®) (NEW) Do not prescribe Allan-Herndon Dudley syndrome associated with MCT-8 deficiency

Reviewed by TAS 22nd June 2021

VERICIGUAT (Verquvo®) (NEW) Grey Chronic heart failure in adult patients with reduced ejection fraction who are stabilised after a recent decompensation event requiring IV therapy.

Not yet reviewed

VIGABATRIN (UPDATED) Yellow Epilepsy

Clarification of historical status

Other Updates on this Website

Recent documents from LMSG and TAS


About the Leicestershire Medicines Strategy Group

In common with other local health communities, the Leicestershire Medicines Strategy Group (LMSG) acknowledges the benefits of having a Leicestershire Health Community-wide strategy for the prescribing of specialist medicines and the managed entry of new drugs and related technologies.

Leicestershire Health Community comprises the three Clinical Commissioning Groups, University Hospitals of Leicester (UHL) NHS Trust and Leicestershire Partnership NHS Trust (LPT), amongst which there is a total consensus on the need for this strategy, and the LMSG has been in place since 2005. Learn more